Pharvaris lands another $80M as it looks to tackle Takeda and CSL with an oral approach for HAE

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Nov 18, 2020 at 11:32 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via A year after their $66 million launch, the Swiss upstart Pharvaris has managed to convince another fleet of new and returning investors to back their upstart approach for a rare genetic condition called hereditary angioedema, or HAE.

    article source